2025-07-22 - Analysis Report
Okay, here's an analysis of Eli Lilly and Co (LLY) based on the provided data.

## Eli Lilly and Co (LLY) Analysis

**Company Overview:** Eli Lilly and Co is a global pharmaceutical company that discovers, develops, and markets pharmaceutical products.

### 1. Performance vs. S&P 500 (VOO)

**Key Figures:**

*   **LLY Cumulative Return:** 241.84%
*   **VOO Cumulative Return:** 97.07%
*   **Absolute Spread:** 150.6
*   **Relative Spread:** 52.5 (Indicates that LLY's outperformance is in the upper half of its historical range compared to VOO.)

**Analysis:** LLY has significantly outperformed the S&P 500 (VOO) over the period covered by the cumulative return data. The relative spread of 52.5 suggests this outperformance is substantial compared to its historical range.

**Alpha, Beta Analysis Table:**

| Year       | CAGR    | MDD   | Alpha   | Beta   | Cap(B) |
| :---------- | :------ | :------ | :------ | :----- | :------ |
| 2015-2017  | 10.0%   | 56.3% | -19.0%  | 0.0    | 75.8   |
| 2016-2018  | 39.0%   | 58.6% | 21.0%   | -0.1   | 103.9  |
| 2017-2019  | 50.0%   | 58.6% | 20.0%   | 0.3    | 118.0  |
| 2018-2020  | 52.0%   | 58.6% | 33.0%   | 0.1    | 151.6  |
| 2019-2021  | 106.0%  | 60.6% | 57.0%   | 0.2    | 248.0  |
| 2020-2022  | 98.0%   | 64.8% | 96.0%   | 0.2    | 328.4  |
| 2021-2023  | 133.0%  | 64.8% | 115.0%  | 0.3    | 523.3  |
| 2022-2024  | 150.0%  | 72.2% | 124.0%  | 0.2    | 693.0  |
| 2023-2025  | 95.0%   | 76.8% | 46.0%   | 0.2    | 684.2  |

**Analysis of Table:**

*   **CAGR:** The Compounded Annual Growth Rate (CAGR) shows significant growth, especially in recent years (2019-2024), peaking at 150%.
*   **MDD:** Maximum Drawdown (MDD) indicates the largest peak-to-trough decline during the period.  MDD has been increasing, suggesting higher volatility.
*   **Alpha:** Alpha represents the excess return compared to the benchmark (S&P 500). High positive alphas in recent years indicate substantial outperformance.
*   **Beta:** Beta measures the stock's volatility relative to the market.  A beta around 0.2-0.3 suggests LLY is less volatile than the market.
*   **Cap(B):** Market capitalization shows very strong growth.

### 2. Recent Stock Price Movements

**Key Figures:**

*   **Current Price:** 762.18
*   **Previous Close:** 771.71
*   **Change:** -1.23
*   **5-Day Moving Average:** 771.39
*   **20-Day Moving Average:** 780.34
*   **60-Day Moving Average:** 778.75

**Analysis:**  The current price is below the 5, 20, and 60-day moving averages, suggesting a short-term downward trend.  The negative change of -1.23 from the previous close confirms recent selling pressure.

### 3. Indicators and Expected Return

**Key Figures:**

*   **MRI (Market Risk Indicator):** 0.3383 (Low Risk)
*   **RSI (Relative Strength Index):** 43.73
*   **PPO (Percentage Price Oscillator):** -0.36
*   **Hybrid Signal:** cash_69%_Sell 69.7% of holdings
*   **20-Day Relative Spread Change:** -3.2 (Short-term decline)
*   **Expected Return:** 146.4% (Over 2+ years vs. S&P 500)

**Analysis:**

*   **MRI:** Indicates a low-risk market environment.
*   **RSI:** An RSI of 43.73 is approaching oversold territory but is not yet there.
*   **PPO:** A negative PPO suggests that the short-term moving average is below the long-term moving average, further confirming a downward trend.
*   **Hybrid Signal:** A high cash ratio (69%) and sell signal indicate a cautious strategy.
*   **Relative Spread Change:** The negative change (-3.2) in the 20-day relative spread indicates recent underperformance compared to the S&P 500.
*   **Expected Return:** The exceptionally high expected return (146.4%) suggests very optimistic long-term growth prospects.

### 4. Recent News & Significant Events

*   **[2025-07-20]:** Major business developments, regulatory changes, or market events.
*   **[2025-07-19]:** Analysts discussing performance and outlook.
*   **[2025-07-22]:** Notable stock volatility.
*   **[2025-07-18]:** Market experts highlight risks and opportunities.

**Analysis:** The news snippets indicate that LLY is subject to significant market attention, influenced by business developments, regulatory changes, analyst evaluations, and volatility.  Investors should monitor these developments closely.

### 5. Recent Earnings Analysis

| Date       | EPS  | Revenue    |
| :---------- | :---- | :--------- |
| 2025-05-01 | 3.07 | 12.73 B$  |
| 2024-10-30 | 1.08 | 11.44 B$  |
| 2024-08-08 | 3.29 | 11.30 B$  |
| 2024-04-30 | 2.49 | 8.77 B$  |
| 2025-05-01 | 2.49 | 8.77 B$  |

**Analysis:**
The most recent EPS is 3.07 and revenue is 12.73 B$.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
| :--------- | :-------- | :------------ |
| 2025-03-31 | $12.73B | 82.53%        |
| 2024-12-31 | $13.53B | 82.24%        |
| 2024-09-30 | $11.44B | 81.02%        |
| 2024-06-30 | $11.30B | 80.80%        |
| 2024-03-31 | $8.77B  | 80.91%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE      |
| :--------- | :-------- | :------- |
| 2025-03-31 | $15.76B | 17.50%   |
| 2024-12-31 | $14.19B | 31.07%   |
| 2024-09-30 | $14.24B | 6.81%    |
| 2024-06-30 | $13.56B | 21.88%   |
| 2024-03-31 | $12.81B | 17.51%   |

**Analysis:**

*   **Revenue and Profitability:** Revenue has shown strong growth over the past year. Profit margins are exceptionally high and stable, indicating strong pricing power and cost control.
*   **Capital and Profitability:** Equity has been increasing, indicating healthy capital accumulation. Return on Equity (ROE) has fluctuated but remains generally strong, suggesting efficient use of shareholder equity.

### 7. Overall Summary

**Summary:**

Eli Lilly and Co (LLY) has demonstrated significant outperformance compared to the S&P 500, driven by strong growth in revenue, high profitability, and efficient capital management. Recent stock price movements suggest a short-term downward trend, with the price falling below key moving averages. The market risk indicator is low, but recent news highlights potential volatility.  The hybrid signal points to a cautious near-term outlook, while the extraordinarily high expected return indicates substantial long-term optimism. Investors should carefully weigh the near-term risks against the longer-term growth potential.

**In conclusion, while the short-term outlook may warrant caution, the long-term prospects for LLY appear very promising based on the financial data and expected return.**
